Veta Genomics Private Limited
Founded in 2022 and headquartered in Kerala, India.
2022 | Thrissur, Kerala (India) | Active
Veta Genomics Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 2 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
About Veta Genomics
Veta Genomics Private Limited (VGPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 23 June 2022 (Two years and eight months 6 days old ). Its registered office is in Thrissur, Kerala, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Hridya, Shaju Kunjalan, Manoj Kumar, and One other member serve as directors at the Company.
Company Details
- Location
Thrissur, Kerala, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U85100KL2022PTC076344
- Company No.
076344
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jun 2022
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Healthcare
Who are the key members and board of directors at Veta Genomics?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neduveliparambil Praveen  | Managing Director | 23-Jun-2022 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Hridya | Director | 23-Jun-2022 | Current |
| Shaju Kunjalan | Director | 10-Nov-2022 | Current |
| Manoj Kumar | Director | 19-Dec-2022 | Current |
Financial Performance of Veta Genomics.
Enhance accessibility to Veta Genomics's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Veta Genomics?
Unlock access to Veta Genomics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Veta Genomics?
Veta Genomics has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Veta Genomics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Veta Genomics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.